Clinical Trial

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This (DEEp OCEAN Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DEE. The study consists of 3 main phases: Screening, Titration period, Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 24 months.
Protocol Amendment History 4 changes
notable Enrollment increased: 292 -> 367 participants 2026-08-13
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-19
notable Trial sites expanded: 110 -> 114 locations 2026-06-13
notable Trial sites expanded: 106 -> 109 locations 2026-04-16
Trial Details
NCT Number NCT06719141
Lead Sponsor Longboard Pharmaceuticals
Conditions Developmental and Epileptic Encephalopathy
Enrollment 367 participants
Start Date 2024-11-11
Primary Completion 2026-10-31 (estimated)
Study Completion 2026-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-12